A Systematic Approach for Liposome and Lipodisk Preclinical Formulation Development by Microfluidic Technology

Abstract

Lipid nanoparticles have transformed the drug delivery field enhancing the therapeutic drug performance of small molecules and biologics with several approved drug products. However, in industry, these more complex drug delivery systems such as liposomes require more material and time to develop. Here, we report a liposome and lipodisk decision tree with model compounds of diverse physicochemical properties to understand how to resourcefully optimize encapsulation efficiency (EE) for these lipid-based drug delivery systems. We have identified trends with physicochemical properties such as Log P, where higher Log P compounds such as curcumin were able to efficiently load into the lipid bilayer resulting in high EE with altering the drug/lipid (D/L) ratio. Moderate Log P compounds such as cyclosporine A and dexamethasone had significantly higher encapsulation in lipodisks, which contain higher amounts of PEG lipid compared to liposomes. The EE of negative Log P compounds, like acyclovir, remained low regardless of altering the D/L ratio and PEG concentrations. In this study, microfluidic techniques were employed to fabricate liposomes and lipodisks formulations allowing for a reproducible strategy for formulation development. Both liposome and lipodisk of curcumin demonstrated enhanced in vivo performance compared with a conventional formulation in the rat pharmacokinetic study. This combination of approaches with multiple model compounds and lipid-based drug delivery systems provides a systematic guidance to effective strategies to generate higher EE with minimal drug waste and expedite the process for preclinical development when applied to industry compounds.

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs

“…The conventional liposomes were prepared through a microfluidics method with the NxGen Blaze (Precision NanoSystems, Vancouver, BC, Canada) system, as previously described in [ 23 ]. First, the DSPC, DSPE-PEG2000, and cholesterol (61.56%:18.8%:19.56% ( w/w )) were dissolved, at a total lipid concentration of 30 mg/mL, in ethanol.…”

A state-of-the-art liposome technology for glioblastoma treatment

“…6V). 51,53 This technology enables the production of small liposome nanoformulations with precise control of their mixing, size, distributions, and fluid flow rate. The main advantages of this technique are its good particle size control, the ability to produce almost all types of vesicles such as SMVs, SUVs, GUVs, and LUVs, and the possibility of upgrading to novel methods for liposome preparation.…”

“…However, its main drawbacks include difficult removal of the organic solvents, unsuitable nature for bulk production, and high cost for microfluidic channels. [51][52][53]…”

Intelligent control of nanoparticle synthesis through machine learning

“…It has the advantage of basically no preprocessing, no advance normalization, and handling missing values. 77 However, it is very prone to overfitting, resulting in poor generalization, and it is difficult to learn for some of the more complex relations. Trinh et al used in vitro characteristics as input parameters (for example, cell line, source, type, and so on).…”